2006
DOI: 10.1097/00128360-200607000-00085
|View full text |Cite
|
Sign up to set email alerts
|

A Health Economic Model to Determine the Cost-effectiveness of Cervical Cancer Screening Methods

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2007
2007
2007
2007

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…In 1 preliminary cost-effectiveness model evaluation, the TIS was judged to be a highly cost-effective screening strategy. 28 The likelihood of cytology-negative patients with a single, positive, HC2 hrHPV DNA test of developing highly significant (CIN31) precancerous or malignant lesions in long-term (10-year) follow-up appears to be very low. In the Portland, Oregon, National Cancer Institute prospective risk study that used conventional Pap smears rather than LBC, the 10-year cumulative risk of developing CIN31 lesions was 3%-6% for conventional cytology-negative HC2 hrHPV DNA-positive women.…”
Section: Discussionmentioning
confidence: 99%
“…In 1 preliminary cost-effectiveness model evaluation, the TIS was judged to be a highly cost-effective screening strategy. 28 The likelihood of cytology-negative patients with a single, positive, HC2 hrHPV DNA test of developing highly significant (CIN31) precancerous or malignant lesions in long-term (10-year) follow-up appears to be very low. In the Portland, Oregon, National Cancer Institute prospective risk study that used conventional Pap smears rather than LBC, the 10-year cumulative risk of developing CIN31 lesions was 3%-6% for conventional cytology-negative HC2 hrHPV DNA-positive women.…”
Section: Discussionmentioning
confidence: 99%